In this study we sought to clarify the role of the proapoptotic potential of mitochondria in the death pathway emanating from the TRAIL (APO-2L) and CD95 receptors in pancreatic carcinoma cells. We focused on the role of the Bcl-2 family member Bcl-X L , using three pancreatic carcinoma cell lines as a model system, two of which have high (Panc-1, PancTuI) and one has low (Colo357) Bcl-X L expression. In these cell lines, the expression of Bcl-X L correlated with sensitivity to apoptosis induced by TRAIL or anti-CD95. Flow cytometric analysis revealed cell surface expression of TRAIL-R1 and TRAIL-R2 on PancTuI and Colo357, and TRAIL-R2 on Panc-1 cells. In Colo357 cells retrovirally transduced with Bcl-X L , caspase-8 activation in response to treatment with TRAIL or anti-CD95 antibody was not dierent from parental cells and EGFP-transfected controls, however, apoptosis was completely suppressed as measured by the mitochondrial transmembrane potential DCm, caspase-3 activity (PARP cleavage) and DNA-fragmentation. Inhibition of Bcl-X L function by overexpression of Bax or administration of antisense oligonucleotides against Bcl-X L mRNA resulted in sensitization of Panc-1 cells to TRAIL and PancTuI cells to anti-CD95 antibodyinduced cell death. The results show that Bcl-X L can protect pancreatic cancer cells from CD95-and TRAILmediated apoptosis. Thus, in these epithelial tumour cells the mitochondrially mediated`type II' pathway of apoptosis induction is not only operative regarding the CD95 system but also regarding the TRAIL system.
Introduction
Apoptosis induced by members of the tumour necrosis factor (TNF) receptor family plays a central role in tissue homeostasis and may in some cellular systems mediate the eects of cytotoxic drugs on neoplastic cells (reviewed by Krammer, 1999) . Dysregulation of this form of cell death may, thus, result in failure of the immune system to eradicate tumour cells in vivo or may lead to resistance towards chemotherapy. Among the cancers that fail to respond to conventional chemotherapy are ductal adenocarcinomas of the pancreas (for review: Bramhall and Neoptolemos, 1997) . Notably, we have found the majority of pancreatic adenocarcinoma cell lines to be largely resistant to CD95-induced apoptosis despite CD95 cell surface expression (Ungefroren et al., 1998) . Resistance to apoptosis induced by CD95 can be the result of dysregulation at distinct steps of the CD95 signalling pathway. Several proteins have been identi®ed that block intracellular signal transduction and caspase activation, e.g. at the receptor/DISC level by inhibiting activation of FLICE/caspase-8, e.g. cellular FLIPs (Irmler et al., 1997; Leverkus et al., 2000) and the protein tyrosine phosphatase FAP-1 (Sato et al., 1995) . In the mitochondria-initiated pathway of apoptosis, caspase activation is triggered by the formation of a multimeric Apaf-1/cytochrome c complex that recruits and activates procaspase-9 (Kluck et al., 1997; Susin et al., 1999) . The activated (initiator) caspase-9 will then cleave and activate downstream caspases such as caspase-3, -6, and -7. Mitochondria-associated activities, like cytochrome c release and loss of the inner mitochondrial membrane potential DCm, are regulated by antiapoptotic members of the Bcl-2 family like Bcl-X L and Bcl-2 (reviewed by Reed, 1998; Kroemer, 1997) . Overexpression of these proteins can provide tumour cells with resistance to a variety of cellular insults including chemotherapeutic drugs in cell culture (Kondo et al., 1998) and in animal models (Liu et al., 1999) . Furthermore, enhanced expression of Bcl-X L has been shown to be associated with a worse prognosis in patients with pancreatic cancer (Friess et al., 1998) . However, the interconnection between cell surface death receptors and mitochondria-initiated pathways and hence the role of Bcl-2-related factors in apoptosis mediated by CD95 has been found to vary among cellular systems. Apoptosis induced by chemotherapeutic drugs or anti-CD95 antibody can be inhibited by Bcl-X L or Bcl-2 in some cell lines (Jaattela et al., 1995, Boise and Thompson, 1997; Kawahara et al., 1998; Kondo et al., 1998; Shinoura et al., 1999) but not in others (Alam et al., 1997; Gross et al., 1999) . Scadi et al. (1998) proposed a model to explain these discrepancies. They suggest the existence of type I cells where Bcl-2 or Bcl-X L confer only marginal protection from apoptosis due to the prevalence of a mitochondria-independent pathway, whereas in type II cells apoptosis is blocked by Bcl-2 and Bcl-X L , since a mitochondrial ampli®cation loop is necessary for ecient apoptosis induction.
TNF-related apoptosis-inducing ligand (TRAIL, APO-2L) is a novel member of the TNF family that can trigger apoptosis by binding to two death domain containing receptors TRAIL-R1/DR4 and TRAIL-R2/ DR5 (Pan et al., 1997a; Walczak et al., 1997) . Two related receptors, TRAIL-R3/DcR1 and TRAIL-R4/ DcR2 both without functional death domains have been identi®ed and postulated to act as decoy receptors Pan et al., 1997b Pan et al., , 1998 . The signalling pathways triggered by TRAIL stimulation and the mechanisms involved in resistance against TRAIL-mediated apoptosis are less well de®ned. FADD/MORT1 and caspase-8 have been shown to be recruited to both, the native TRAIL-R1 and TRAIL-R2 DISC upon ligand-induced receptor crosslinking (Kischkel et al., 2000; Sprick et al., 2000) . In addition, these two signalling proteins were shown to be essential for TRAIL-R2-induced apoptosis (Bodmer et al., 2000; Sprick et al., 2000) . Recently, it was reported that TRAIL induces caspase-8-mediated cleavage of the pro-apoptotic protein Bid, with subsequent loss of the mitochondrial transmembrane potential DCm (Yamada et al., 1999; Keogh et al., 2000; Walczak et al., 2000) , suggesting the participation of mitochondria in TRAIL-induced apoptosis. However, in multiple myeloma as well as lymphoid cell lines TRAIL-induced apoptosis was not blocked by Bcl-2 (Gazitt, 1999; Keogh et al., 2000; Walczak et al., 2000) . Thus, a similar situation as in CD95-mediated apoptosis emerges, as it is unclear to what extent the mitochondrial pro-apoptotic potential contributes to TRAIL-induced apoptosis in epithelial cells and whether other Bcl-2 related proteins are capable of interfering with it.
Prompted by the initial observation of a general high Bcl-X L expression in pancreatic carcinoma tissues (Friess et al., 1998; Miyamoto et al., 1999) , and the known ability of Bcl-X L to protect cells from a wide variety of apoptotic stimuli, we investigated the potential role of Bcl-X L in TRAIL-and CD95-induced apoptosis in pancreatic adenocarcinoma cells. Here, we demonstrate that Bcl-X L protects pancreatic carcinoma cells not only from CD95 but also from TRAILinduced apoptosis. We also show that Bax sensitizes these cells to both forms of apoptosis presumably by the ability to antagonize the antiapoptotic function of Bcl-X L . Thus, this is the ®rst study that presents a protective eect of Bcl-X L in epithelial cancer cell lines in the TRAIL signalling pathway.
Results

Relative sensitivity of pancreatic carcinoma cells to TRAIL-mediated apoptosis
The death receptors CD95, TRAIL-R1, TRAIL-R2 and TNF-R1 are known to share common positive and negative signal transducers, eventually resulting in a similar biological response. In a previous study we have found that the majority of human pancreatic carcinoma cell lines was refractory to CD95 triggering. Here we analysed a subset of these cell lines for their sensitivity to TRAIL-mediated cytotoxicity. The cell lines Panc-1 and PancTuI were largely refractory to a 24 h treatment with anti-CD95 (CH11, 0.1 ± 1000 ng/ml) ( Figure 1a ) and to recombinant human TRAIL (0.1 ± 1000 ng/ml) (Figure 1b) . In contrast, the Colo357 cells readily underwent apoptosis induced either by TRAIL or by anti-CD95 (Figure 1b) . DNA fragmentation was essentially complete 2 ± 4 h after addition of TRAIL, and 4 ± 6 h after addition of anti-CD95 (data not shown). To determine the participation of mitochondria in TRAIL and CD95-induced apoptosis we monitored the mitochondrial permeability transition (PT) at dierent time points in Colo357 cells. Loss of DCm was detectable as early as 15 min after addition of TRAIL but did not occur until 2 h following CD95 stimulation ( Figure 1c) . Triggering of the mitochondrial pathway may result in activation of the executioner caspase-3 and cleavage of its substrate PARP. As shown in Figure 4c , PARP cleavage in Colo357 cells is detectable at 2 h (TRAIL) and 4 h (anti-CD95), respectively, and thus follows loss of DCm.
Expression of TRAIL-R1 and TRAIL-R2 in pancreatic carcinoma cells
We employed¯ow cytometry using speci®c monoclonal antibodies (mAb) to TRAIL-R1 and TRAIL-R2 to correlate cell surface expression of these receptors with resistance to TRAIL. TRAIL-R2 was expressed on all three cell lines whereas much lower amounts of TRAIL-R1 were present on PancTuI, and Panc-1 cells ( Figure  2 ). TRAIL-R1 was undetectable on Colo357 cells ( Figure 2 ) but it was shown recently that TRAIL has the highest anity to TRAIL-R2 (Truneh et al., 2000) . Previously, we have demonstrated surface expression of CD95 in several carcinoma cell lines of pancreatic origin, among them Colo357 and PancTuI cells (Ungefroren et al., 1998) . However, CD95 expression could not be detected on the surface of Panc-1 cells (A Trauzold and H Ungefroren, unpublished observation).
Expression of Bcl-X L in pancreatic carcinoma cells
To explore the molecular basis of the dierential sensitivity to death receptor-mediated apoptosis in pancreatic carcinoma cells, we evaluated the expression level of the anti-apoptotic proteins Bcl-X L and Bcl-2 in pancreatic carcinoma cell lines. A survey of 12 dierent cell lines by Northern blot analysis indicated that Bcl-X L is highly expressed (Figure 3a ) while Bcl-2 expression was rather low (data not shown). Among these cell lines, the expression of Bcl-X L was particularly low in Colo357 cells (Figure 3a ,b). The expression levels of Bcl-X L correlated well with sensitivity to apoptosis induced by TRAIL and anti-CD95.
Effect of overexpression of Bcl-X L on TRAIL and CD95-mediated apoptosis in pancreatic carcinoma cells
The low levels of Bcl-X L expression in Colo357 cells correlated with a moderate sensitivity to CD95-and a high sensitivity to TRAIL-induced apoptosis ( Figure  1 ). Thus, in order to study whether overexpression of Bcl-X L aected death receptor-mediated apoptosis we stably expressed Bcl-X L in Colo357 cells (Figure 4a) . The cells were then tested for their susceptibility towards CD95-and TRAIL-induced apoptosis (Figure 4b ± d) . Viability of Colo357-bcl-xL cells (as measured by DNA fragmentation) was strongly increased in contrast to parental and EGFP-transduced control cells. After incubation with anti-CD95 or TRAIL for 24 h, Colo357-bcl-xL cells remained viable even at high concentrations of the apoptosis inducers (Figure 4b ). Bcl-X L overexpression resulted in inhibition of caspase-3 activity (as determined by PARP cleavage, Figure  4c ), as well as prevention of the loss of DCm (Table 1) . Transduction of Colo357 cells with Bcl-X L did not aect the expression level of Bax (Figure 4a ) or procaspase-3 (not shown) nor did it induce more eective DISC formation since the extent and kinetics of procaspase-8/8a cleavage was not dierent between Colo357-bcl-xL and Colo357-EGFP control cells ( Figure 4d ). This experiment also revealed that caspase-8 cleavage in these cells is detectable 2 h after addition of TRAIL and 4 h after addition of anti-CD95. Altogether, these results demonstrate that Bcl-X L can confer protection against TRAIL-and anti-CD95-induced apoptosis at the level of mitochondria.
Effect of specific inhibition of Bcl-X on anti-CD95 and TRAIL-induced apoptosis
To inhibit the function of Bcl-X L , two approaches were chosen: (i) overexpression of the pro-apoptotic protein Bax, the natural dimerization partner of Bcl-X L , in PancTuI and Colo357 cells, and (ii) blocking of Bcl-X L synthesis with speci®c antisense oligonucleotides in PancTuI and Panc-1 cells. Overexpression of Bax in PancTuI (Figure 5a ), a cell line that expresses high levels of Bcl-X L , rendered these cells partially sensitive to anti-CD95-induced apoptosis (Figure 5b) . Similarly, transduction of Colo357 cells with Bax (Colo357-bax, Figure 4a ) further enhanced CD95-and TRAILinduced loss of DCm (Table 1) and DNA fragmentation (data not shown). To reduce the expression of Bcl-X L , we used Bcl-X antisense oligonucleotides (300 nM) which have previously been shown to eectively suppress Bcl-X L protein levels in MKN-45 gastric cancer cells (Kondo et al., 1998) and Human Umbilical Vein Endothelial Cells (HUVEC) (Ackermann et al., 1999) . PancTu1 and Panc-1 cells transfected with Bcl-X antisense oligonucleotides showed a marked reduction of Bcl-X L protein levels ( Figure 6 ). Suppression of Bcl-X L protein levels in Panc-1 and PancTu1 cells by antisense oligonucleotide treatment led to a signi®cant decrease in survival after anti-CD95-and TRAILinduced apoptosis on PancTu1 and Panc-1 cells, respectively ( Figure 6 ). Treatment of Panc-1 cells with anti-CD95 had no eect (data not shown) which is in agreement with the observation that these cells lack detectable CD95 surface expression. It should be mentioned that the two Bcl-X L antisense oligonucleotides used here target both the long and short forms of Bcl-X (Bcl-X L and Bcl-X s ). However, since Bcl-X s is undetectable at the protein level in both Panc-1 and PancTu1 cells (data not shown), the eects observed can be considered speci®c for Bcl-X L .
Oncogene Bcl-X L protection from CD95 and TRAIL-induced apoptosis S Hinz et al
Discussion
In this study we sought to clarify the role of the antiapoptotic protein Bcl-X L in CD95-and TRAILmediated apoptosis in pancreatic adenocarcinoma. When initiating this study, some controversy prevailed as to the involvement of mitochondria in cell death mediated by CD95, whereas no such data were available for the TRAIL-receptor pathway. In the case of CD95, a wealth of data now suggests that in the majority of cell types Bcl-X L (and Bcl-2) indeed can exert a protective eect (Boise and Thompson, 1997; Schneider et al., 1997; Scadi et al., 1998; Kawahara et al., 1998; Kondo et al., 1998; Shinoura et al., 1999) , whereas other CD95 expressing cells are not protected (Memon et al., 1995; Strasser et al., 1995; Alam et al., 1997; Scadi et al., 1998; Gross et al., 1999) . Our data on constitutive expression, over-expression and antisense oligonucleotide and Bax-mediated inhibition experiments clearly demonstrate an important role for Bcl-X L in modulating not only the CD95 but also the TRAIL-receptor pathways in pancreatic carcinoma cells. However, the mechanisms by which Bcl-2-like proteins accomplish inhibition of death receptorinduced apoptotic signals may dier. The overexpression data revealed that Bcl-X L eectively pre- vented loss of DCm and, subsequently, activation of caspase-3 and DNA fragmentation in both receptor pathways, thus acting at the level of the mitochondria. Bcl-X L in pancreatic carcinoma cells does not seem to block cell death by inhibiting death receptor-induced recruitment to CD95 and processing of procaspase-8 (see Figure 4d) as it was described for Bcl-2 in Jurkat cells (Kawahara et al., 1998) .
Our study clearly showed that Bcl-X L can inhibit cell death pathways originating from CD95 at the level of mitochondrial function; hence pancreatic duct epithelial cells can be considered as cells where the type II pathway with respect to CD95-induced apoptosis is operative according to the model suggested by Scadi et al. (1998) . This model predicts that upon activation of CD95 in type II cells only insucient amounts of active caspase-8 are generated at the DISC which do not allow for eective downstream activation of caspase-3 (and possibly caspase-7). Instead, Bid is cleaved in a caspase-8-dependent fashion, translocates to mitochondria and then triggers the mitochondrial changes that ultimately result in apoptosome formation, caspase-3 activation and DNA fragmentation. This series of events is likely to occur in Colo357 cells since loss of DCm was ®rst detectable 2 h after addition of anti-CD95, a time when caspase-8 had already partially been cleaved (compare Figures 1c and  4d ) and both changes preceded the appearance of PARP cleavage at 4 h.
In contrast to the apoptotic signal transduced by CD95, TRAIL-induced apoptosis occurred more rapidly with loss of DCm being detectable as early as 15 min following TRAIL stimulation. Although caspase-8 cleavage was not detectable by conventional Western blot analysis in EGFP-and Bcl-X L -transduced Colo357 cells at 0.5 h after TRAIL addition, small amounts of active caspase-8, too low to be detectable by this method, may be generated within a few minutes after ligand binding. This caspase-8 activity is sucient to trigger subsequent loss of DCm via Bid cleavage. Bid cleavage by caspase-8 upon TRAIL stimulation was reported recently (Yamada et al., 1999; Keogh et al., 2000) . Evidence for the involvement of mitochondria in the TRAIL death pathway also came from other factors known to act further up-or downstream of Bcl-X L in the mitochondrial pathway. Caspase-9S, a naturally occurring dominant negative inhibitor of caspase-9, inhibited apoptosis induced by TRAIL and Bax (Seol and Billiar, 1999) and activation of caspase-9 correlated with sensitivity to TRAIL-induced cell death . Finally, in Apaf-1 7/7 cells TRAIL-induced apoptosis was partially inhibited (Perkins et al., 2000) . Activation of caspase-3 has been described after TRAIL-R stimulation in various cell types (KothnyWilkes et al., 1999; Yamada et al., 1999; Kim et al., 2000; Sprick et al., 2000) , and is now also observed in pancreatic carcinoma cells. Our ®ndings on the antiapoptotic function of Bcl-X L in TRAIL-induced apoptosis of (pancreatic) carcinoma cells contrast with our recent observations in transformed lymphocytes where TRAIL-induced cell death bypassed mitochondria by direct caspase-8-mediated activation of downstream caspases. TRAIL-induced apoptosis could still occur in these cell lines even upon Bcl-2 and Bcl-X L overexpression Keogh et al., 2000) . This situation is reminiscent of the type I/II pathways operative in the CD95 system (Scadi et al., 1998) . Thus, it appears that the type I/II pathway model originally identi®ed as cell type-speci®c for the CD95 apoptosis system may also be applicable to apoptosis induced by TRAIL. However, our data on the TRAIL system indicate that instead of being cell type-speci®c it rather seems to be speci®c for individual pathways triggered by the dierent apoptosis-inducing receptors. Yet, the biochemical nature of these dierences for the individual death receptor pathways remains unde®ned.
Despite a major role for Bcl-X L in conferring resistance to death receptor-mediated cell death, some heterogeneity in the pattern of molecular alterations may exist among dierent pancreatic tumour lines as it was found in a survey of human melanoma cell lines with regard to the TRAIL system (Zhang et al., 1999) . Resistance may occasionally be the result of inecient receptor translocation from the ER to the cell surface or genomic loss or loss-of-function mutations of TRAIL-R1 and/or TRAIL-R2 genes (Zhang et al., 1999; Lee et al., 1999; Kim et al., 2000) . In addition, the expression of TRAIL receptors with a putative decoy function may contribute to resistance to TRAIL (Pan et al., 1997b; Sheridan et al., 1997) . However, PancTu1, Panc-1 and Colo357 cells did not express TRAIL-R3 and TRAIL-R4 (A Trauzold, manuscript in preparation). Previously, it has been shown that the expression of these presumably antagonistic receptors was not responsible for resistance to TRAIL in keratinocytes (Leverkus et al., 2000) and this is also likely to be the case in pancreatic tumour cells. Another protein that can protect cells from death receptor-induced apoptosis is NF-kB. Although its role in TRAIL-induced apoptosis is still controversial, recent data from our laboratory indicated that pancreatic carcinoma cell lines generally express high constitutive levels of this transcription factor and that interfering with NF-kB expression sensitized these cells to TRAIL-induced apoptosis (A Trauzold, manuscript in preparation). This observation may be signi®cant in the light of a recent report showing that NF-kB transcriptionally upregulated the expression of Bcl-X L (Chen et al., 2000) . Colo357 parental and transduced clones were stimulated with 100 ng/ ml anti-CD95 or 100 ng/ml TRAIL for 24 h followed by staining with Mitosensor reagent as outlined in Figure 1c . Data are expressed as the mean percentage of cells+s.d. with intact~Cm (n=3) TRAIL has been shown to exert tumoricidal activity in vitro (Wiley et al., 1995; Pitti et al., 1996; Grith et al., 1998) and in vivo (Walczak et al., 1999; Ashkenazi et al., 1999) . Importantly, although TRAIL-mediated apoptosis has been observed in both, primary human astrocytes (Walczak et al., 1999) and hepatocytes (Jo et al., 2000) , no toxic side eects could be detected upon systemic treatment of mice and cynomolgous monkeys with TRAIL and APO-2L, respectively (Walczak et al., 1999; Ashkenazi et al., 1999) . The observation that mitochondrial anti-apoptotic proteins like Bcl-X L may inhibit the cytotoxic activity of TRAIL will have to be considered in the use of TRAIL as an anti-tumour agent in tumours that over-express Bcl-X L , especially those of the gastrointestinal tract (Kondo et al., 1996 (Kondo et al., , 1998 including pancreatic adenocarcinomas (Friess et al., 1998; Miyamoto et al., 1999 ). Yet, successfully interfering with Bcl-X L function in such tumour cells may not only restore sensitivity to chemotherapy but also to TRAIL.
Materials and methods
Cell lines and cell culture
The human pancreatic carcinoma cell lines Colo357 and PancTuI and their suppliers have been described previously (Ungefroren et al., 1998) . The Panc-1 cell line was obtained from ATCC. Non-genetically engineered cells were routinely maintained in RPMI 1640 supplemented with 10% FCS, 2 mM glutamine and 1 mM sodium pyruvate (Life Technologies, Inc., Eggenstein, Germany) without penicillin and streptomycin, whereas retrovirally transduced cells received puromycin (5 mg/ml, Sigma, Deisenhofen, Germany) in addition. All cells were kept in a water-saturated atmosphere containing 5% CO 2 at 378C. 
Immunological reagents
The anti-human TRAIL-R1 and TRAIL-R2 mAbs were kindly provided by Immunex Corp. (Seattle, USA). Recombinant human TRAIL was supplied by R&D Systems (Wiesbaden, Germany). The monoclonal ab (mAb) against human CD95, CH11, was purchased from Coulter Immunotech (Heidelberg, Germany). The rabbit anti-Bcl-X L and antiBax abs used for Western blotting were obtained from PharMingen (Hamburg, Germany). The anti-actin mAb AC-15 was obtained from Sigma, an ab to PARP (Ab-2) from Calbiochem (Bad Soden, Germany) and a mAb to caspase-8 from Upstate Biotechnology (Biozol, Eching, Germany).
RNA isolation and Northern blot analysis
Total RNA was isolated with RNA Clean (AGS, Heidelberg, Germany) according to the manufacturers instructions. Northern blots were prepared after separation of total RNA in 1.2% formaldehyde gels blotted onto Hybond N membranes (Amersham Buchler, Braunschweig, Germany) and hybridized as described previously (Ungefroren and Krull, 1996) . As probes the entire cDNA of bcl-X L (see below) and a 206 bp fragment (nucleotides 358 ± 563) of human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used following labelling with 32 P-dCTP (3000 Ci/mmol, Amersham Buchler) and separated from unincorporated label using Nick columns (Pharmacia, Uppsala, Sweden). The resulting ®lters were washed at high stringency and autoradiographed on Kodak X-omat AR X-ray ®lm (Kodak, Rochester, NY, USA).
Construction of expression vectors for Bcl-X L -related proteins and stable integration into pancreatic tumour cells
The entire coding sequence of the human bcl-X L gene was ampli®ed by RT ± PCR from Colo357 pancreatic carcinoma cell total RNA using Pfu polymerase (Stratagene, San Diego, CA, USA). The oligonucleotide primers were from the 5' and 3' untranslated regions: bcl-X L -sense: 5'-TTGGACAATG-GACTGGTTGA-3', bcl-X L -antisense: 5'-GTAGAGTG-GATGGTCAGTG-3' (Gauthier et al., 1996) . Dr JC Reed (The Burnham Institute, San Diego, CA, USA) generously provided a cDNA for the human Bax protein. Bcl-X L , Bax and EGFP cDNAs were inserted in sense orientation into the retroviral vector pBABE-puro (Morgenstern and Land 1990) and the resulting constructs were co-transfected into 293T producer cells along with retroviral packaging vectors as described previously (Howard et al., 2000) . To prevent apoptosis of 293T cells and to obtain high titers of retroviral particles, the pBABE-bax vector was co-transfected with a non-retroviral Bcl-X L expression vector. Retroviral particles released by 293T cells were used to infect Colo357 cells (Bcl-X L , Bax and EGFP) and PancTuI cells (Bax and EGFP). Pools of productively infected cells (obtained by selection with puromycin (5 mg/ml, Sigma)) were taken for analysis.
Apoptosis assays
DNA fragmentation during apoptosis was detected using the JAM test, which was carried out as described previously (Ungefroren et al., 1998) with some modi®cations. Brie¯y, pancreatic tumour cells were seeded at a density of 1 ± 2610 4 cells/well into 96-well¯at bottom microtiter plates, allowed to adhere overnight and labelled with 3 H-thymidine (370 KBq/ ml; Amersham-Buchler, Braunschweig, Germany). Subsequently, cells were washed with PBS and incubated with recombinant human TRAIL or the anti-CD95 mAb CH11 in normal growth medium for 24 or 48 h. Cells were then lysed in 0.05% SDS for 30 min at 378C to ensure complete release of genomic DNA and harvested by vacuum aspiration on glass ®bre ®lters. Dried ®lters were counted into a liquid scintillation counter (Wallac, Switzerland). The percentage of speci®c DNA fragmentation, indicative of apoptosis, was calculated as: per cent viability=(E/S)6100, where E (experimental) is c.p.m. of retained DNA in the presence of anti-CD95 or TRAIL and S (spontaneous) is c.p.m. of retained DNA in the absence of anti-CD95 or TRAIL. Caspase-3 activity was measured by immunoblotting of total cellular proteins and subsequent detection of PARP cleavage. Mitochondrial integrity was determined by assessing loss of the mitochondrial transmembrane potential DCm using the ApoAlert Mitochondrial Membrane Sensor Kit (Clontech, Heidelberg, Germany) followed by FACSscan (Becton Dickinson) analysis.
Immunoblot analysis
Preparation of protein extracts was carried out as described previously (Ungefroren et al., 1998) . For immunoblotting, 40 mg of total cellular protein (measured with BCA Protein Assay Reagent, Pierce Chemical Co., IL, USA, according to the manufacturer's instructions) were separated by 12.5% SDS ± PAGE and transferred to a PVDF membrane (Immobilon-P; Millipore, Eschborn, Germany). Membranes were blocked with PBS containing 5% non-fat dry milk overnight at 48C, washed several times with PBS containing 0.2% Tween 20 (PBS/Tween) and then incubated with the primary ab. After washing with PBS/Tween, blots were incubated with the appropriate peroxidase-conjugated secondary antibodies and developed with the chemiluminescent detection kit (ECL kit, Amersham-Buchler, Germany) following the manufacturer's protocol.
Flow cytometric analysis
EDTA-released cells (5610 5 ) obtained from monolayer cultures were incubated with anti-TRAIL-R1 or anti-TRAIL-R2 mouse mAbs (1 : 100 in PBS/1% BSA) or isotype-matched control mAb for 1 h at 48C, washed twice in ice cold PBS containing 0.05% sodium azide (PBS/azide) and incubated with anti-mouse biotin-conjugated secondary ab for additional 40 min at 48C in the dark. After two further washes with PBS/azide, cells were incubated with phycoerythrin-conjugated streptavidin, washed again twice as before and resuspended in 300 ml 1% paraformaldehyde in PBS prior to FACS analysis. As a control the¯uorescence of cells incubated with the appropriate isotype matched antibodies followed by labelling with the corresponding secondary ab was measured. Flow cytometric analysis was carried out using a FACScan (Becton Dickinson, Heidelberg, Germany) and analysed with the`Cell Quest' program. At least 10 000 cells were examined for each determination with the window set to exclude cellular debris and non-viable cells.
Oligonucleotide treatment
Cells were treated with either antisense-, sense-or controlphosphorothioate-modi®ed oligonucleotides either spanning the ATG start codon of the human Bcl-X mRNA (Kondo et al., 1998) : 5'-CCCGGTTGCTCTGAGACATT-3' (antisense-134) or 5'-AATGTCTCAGAGCAACCGGG-3' (sense-134) or against an internal region of the coding sequence (Ackermann et al., 1999) : 5'-CTACGCTTTCCACGCACAGT-3' (antisense-581) or 5'-CGACACGTACCTCTCGCATT-3' (control-581). Cells (10 4 ) were seeded in 96-well plates, labelled on the following day with 3 H-thymidine and subsequently incubated with Bcl-X L oligonucleotides (300 nM) in the presence of Lipofectin (10 mg/ml, Life Technologies) in the case of PancTuI or LipofectAmin 2000 (20 mg/ml, Life Technologies) in the case of Panc-1 for 4 ± 6 h. After removal of the transfection mixture, cells were incubated with normal medium for additional 24 h (PancTuI) or 48 h (Panc-1) prior to induction of apoptosis by anti-CD95 or TRAIL, respec-tively. The delay period allowed for reduction in Bcl-X L protein prior to the addition of the apoptosis-inducing ligands. Apoptosis was determined by the JAM test 24 h after addition of anti-CD95 or TRAIL at the indicated concentrations.
Abbreviations ATCC, American type culture collection; DISC, deathinducing signalling complex; EGFP, enhanced green¯uor-escent protein; FACS,¯uorescence activated cell sorting; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; monoclonal (m) antibody (ab); PAGE, polyacrylamide gel electrophoresis; PARP, poly(ADP-ribose) polymerase; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.
